Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310341 | 0.89 | MAPT (0.42) | MAPTGRM5GRM1HPGDL3MBTL1 | |
| SCHEMBL5759027 | 0.81 | MAPT (0.38) | MAPTACHEGRIN2BAGPAT2GRM5 | |
| SCHEMBL1523749 | 0.73 | AADAT (0.48) | MAPTL3MBTL1TP53TSHR | |
| SCHEMBL1523750 | 0.73 | AADAT (0.48) | MAPTL3MBTL1TP53TSHR | |
| SCHEMBL30254699 | 0.73 | UCHL1 (0.39) | GRM5GRM1 | |
| SCHEMBL23290493 | 0.72 | L3MBTL1 (0.40) | GRM5GRM1L3MBTL1 | |
| SCHEMBL429243 | 0.71 | SSTR4 (0.38) | GRM5 | |
| SCHEMBL7970683 | 0.71 | PDK4 (0.51) | GRM5GRM1 | |
| SCHEMBL5758095 | 0.71 | MAPT (0.41) | MAPTGRM5GRM1HPGDL3MBTL1 | |
| SCHEMBL16272011 | 0.70 | GPR119 (0.45) | GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844344-B2 | Benzofuran derivatives | ELI LILLY AND COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030232833-A1 | Benzofuran derivatives | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1246822-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001046177-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232833-A1 | Benzofuran derivatives | BRD1, BPTF, HTR1F | MAPT 1416/4885ACHE 477/4885GRIN2B 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.